Aims
Highly interdisciplinary research focused on the pre-clinical development of novel synthetic small organic molecules cancer therapeutics. Laboratory utilizing organic molecules synthesis for the development of anti-cancer therapeutic based on small molecules and peptide based targeted drug delivery system against different types of cancer.  Objective is to create a pathway which bridge between chemist and biologist to translate synthetic anticancer molecules for further validation against in vitro/in vivo model cancer model.  The work will be carried out with biologists and drug discovery chemist together for the development of novel targeted cancer therapeutics.

​

Latest News (Patent/publication in 2025-2026)

1.  R Roy, T Ria, K Das, V Patial, G Das, U H Sk, "A Rationally Engineered Norfloxacin–Phenoxazine Hybrid as a Dual-Function Anticancer Agent: DNA Intercalation Synergizes with Topoisomerase II Inhibition against Murine Breast Tumor." ACS Med. Chem. Lett., 2026 (In Press).

2. S Sharma, R Roy, A Vartak, E Sen, UH Sk*, "Synthesis and characterization of a novel Naphthalimide-Selenium based Temozolomide drug conjugate in glioma cells". Bioorganic Chemistry, 2025, 154, 107998

3. A Halder, T Ria, S Chowdhury, B Mondal, UH Sk, R Maity, "Cytotoxic Effects of Mono- and Trinuclear Platinum(II)–N-Heterocyclic Carbene Complexes against Triple-Negative Breast Cancer Cell Lines". Inorg. Chem. 2026, 65 (1): 1–6